Daxor Co. (NASDAQ:DXR) Short Interest Down 8.3% in January

Daxor Co. (NASDAQ:DXR) saw a large drop in short interest in the month of January. As of January 31st, there was short interest totalling 12,100 shares, a drop of 8.3% from the January 15th total of 13,200 shares. Currently, 0.6% of the company’s shares are sold short. Based on an average daily volume of 16,500 shares, the days-to-cover ratio is presently 0.7 days.

Institutional Investors Weigh In On Daxor

An institutional investor recently raised its position in Daxor stock. Keyes Stange & Wooten Wealth Management LLC raised its stake in Daxor Co. (NASDAQ:DXR) by 34.8% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 14,612 shares of the company’s stock after purchasing an additional 3,771 shares during the quarter. Keyes Stange & Wooten Wealth Management LLC owned 0.30% of Daxor worth $126,000 at the end of the most recent quarter. 1.34% of the stock is currently owned by institutional investors.

Daxor Stock Performance

NASDAQ DXR traded up $0.05 during trading on Tuesday, hitting $7.23. 1,158 shares of the company’s stock traded hands, compared to its average volume of 5,662. The stock has a fifty day moving average of $7.92 and a two-hundred day moving average of $8.61. Daxor has a 12-month low of $6.55 and a 12-month high of $10.00.

About Daxor

Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions.